Miripla（MIRIPLA for intra-arterial injection ミリプラ用懸濁用液4mL）
MIRIPLA for intra-arterial injection（Miriplatin Hydrate）
Brand name : MIRIPLA for intra-arterial injection 4mg
Active ingredient: Miriplatin Hydrate
Dosage form: injection
Print on wrapping:
Effects of this medicine
This medicine suppresses growth of cancer cells.
It is administered through hepatic artery and usually used to treat liver cancer.
Before using this medicine, be sure to tell your doctor and pharmacist
If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
If you have thyroid disorder or liver disorder.
If you are pregnant, possibly pregnant or breastfeeding.
If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>>
In general, administer into the liver once a day.
The treatment period with this medicine depends on your symptoms.
Precautions while taking this medicine
You may have a fever 1 week or later after administration.
Possible adverse reactions to this medicine
The most commonly reported adverse reactions include fever, nausea/vomiting, pain at the injection site, loss of appetite, dull, chill, diarrhea, back pain, headache, rash/eczema, cough, abdominal pain, and constipation. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
general malaise, loss of appetite, nausea [liver dysfunction, jaundice, liver failure]
chill, acute high fever with shivering, tachycardia [infections]
anemic symptoms, fever, bleeding tendency [myelosuppresion]
fever, cough, respiratory distress [interstitial pneumonia]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Storage conditions and other information
If you become unwell during injection, you should tell your doctor immediately.
Sumitomo Dainippon Pharma Co.,Ltd. Injection
Revised: 7/2015
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment. |
